Matches in SemOpenAlex for { <https://semopenalex.org/work/W2335251708> ?p ?o ?g. }
- W2335251708 endingPage "835" @default.
- W2335251708 startingPage "825" @default.
- W2335251708 abstract "In the present work, we report on the solubilization of gabapentin (GBP) into lyotropic hexagonal mesophases composed of monoolein, tricaprylin, and water. It was demonstrated that the hexagonal structure remained intact up to 2 wt % gabapentin, whereas the lamellar phase coexisted with the hexagonal one in the concentration range of 3−4 wt % of the drug. At gabapentin content of 5−6 wt %, only lamellar phases containing defects such as dislocations and multilamellar vesicles were detected. Incorporation of GBP decreased the lattice parameter of the HII mesophase from 56.6 to 50.6 Å, while the structural dimensions of the lamellar phase were not affected. ATR−FTIR analysis suggested enhanced hydrogen bonding between the protonated amine of GBP and the O−H groups of the GMO and the water surrounding in the inner hydrophilic interface region. This led to intercalation of the drug into the water−lipid interface. At higher GBP loads of 4−6 wt %, thermal analysis revealed disordering within the lipid packing, apparently induced by the spatially altered interface area. Rheological measurements correlated the macroscopic features of the systems with alterations on the molecular level and allowed distinguishing between closely related mesophases due to their different rheological characteristics. In vitro transdermal delivery studies showed that the examined mesophases enabled a sustained release of GBP compared to its aqueous solution. Sustained release was more pronounced in the case of the hexagonal mesophase, compared to the lamellar one." @default.
- W2335251708 created "2016-06-24" @default.
- W2335251708 creator A5003332003 @default.
- W2335251708 creator A5018932295 @default.
- W2335251708 creator A5024670229 @default.
- W2335251708 creator A5025465922 @default.
- W2335251708 date "2010-12-23" @default.
- W2335251708 modified "2023-09-23" @default.
- W2335251708 title "Solubilization of Gabapentin into H<sub>II</sub> Mesophases" @default.
- W2335251708 cites W1535948728 @default.
- W2335251708 cites W1965714113 @default.
- W2335251708 cites W1965723868 @default.
- W2335251708 cites W1965918725 @default.
- W2335251708 cites W1968282972 @default.
- W2335251708 cites W1971807336 @default.
- W2335251708 cites W1972084252 @default.
- W2335251708 cites W1979601633 @default.
- W2335251708 cites W1981047979 @default.
- W2335251708 cites W1981537077 @default.
- W2335251708 cites W1992468948 @default.
- W2335251708 cites W1999972617 @default.
- W2335251708 cites W2002448996 @default.
- W2335251708 cites W2004530075 @default.
- W2335251708 cites W2006894956 @default.
- W2335251708 cites W2010482986 @default.
- W2335251708 cites W2012714739 @default.
- W2335251708 cites W2014670473 @default.
- W2335251708 cites W2022246438 @default.
- W2335251708 cites W2023795428 @default.
- W2335251708 cites W2028025122 @default.
- W2335251708 cites W2028420075 @default.
- W2335251708 cites W2030426447 @default.
- W2335251708 cites W2033573454 @default.
- W2335251708 cites W2033604843 @default.
- W2335251708 cites W2035477196 @default.
- W2335251708 cites W2036193810 @default.
- W2335251708 cites W2039982019 @default.
- W2335251708 cites W2040196445 @default.
- W2335251708 cites W2043564745 @default.
- W2335251708 cites W2043765535 @default.
- W2335251708 cites W2044178361 @default.
- W2335251708 cites W2045432121 @default.
- W2335251708 cites W2048195319 @default.
- W2335251708 cites W2048682241 @default.
- W2335251708 cites W2048695489 @default.
- W2335251708 cites W2049890028 @default.
- W2335251708 cites W2051392583 @default.
- W2335251708 cites W2056267770 @default.
- W2335251708 cites W2057983296 @default.
- W2335251708 cites W2061809213 @default.
- W2335251708 cites W2063967931 @default.
- W2335251708 cites W2065853078 @default.
- W2335251708 cites W2068726926 @default.
- W2335251708 cites W2069310949 @default.
- W2335251708 cites W2069612278 @default.
- W2335251708 cites W2069850786 @default.
- W2335251708 cites W2072132948 @default.
- W2335251708 cites W2073809289 @default.
- W2335251708 cites W2074324958 @default.
- W2335251708 cites W2075122788 @default.
- W2335251708 cites W2077863217 @default.
- W2335251708 cites W2082389157 @default.
- W2335251708 cites W2087843930 @default.
- W2335251708 cites W2088812259 @default.
- W2335251708 cites W2088973502 @default.
- W2335251708 cites W2095383648 @default.
- W2335251708 cites W2103289578 @default.
- W2335251708 cites W2107721698 @default.
- W2335251708 cites W2108460780 @default.
- W2335251708 cites W2128803340 @default.
- W2335251708 cites W2339279963 @default.
- W2335251708 cites W3042413953 @default.
- W2335251708 cites W4245528808 @default.
- W2335251708 cites W4249671208 @default.
- W2335251708 doi "https://doi.org/10.1021/jp108801d" @default.
- W2335251708 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21182317" @default.
- W2335251708 hasPublicationYear "2010" @default.
- W2335251708 type Work @default.
- W2335251708 sameAs 2335251708 @default.
- W2335251708 citedByCount "15" @default.
- W2335251708 countsByYear W23352517082012 @default.
- W2335251708 countsByYear W23352517082014 @default.
- W2335251708 countsByYear W23352517082017 @default.
- W2335251708 countsByYear W23352517082018 @default.
- W2335251708 countsByYear W23352517082019 @default.
- W2335251708 countsByYear W23352517082022 @default.
- W2335251708 crossrefType "journal-article" @default.
- W2335251708 hasAuthorship W2335251708A5003332003 @default.
- W2335251708 hasAuthorship W2335251708A5018932295 @default.
- W2335251708 hasAuthorship W2335251708A5024670229 @default.
- W2335251708 hasAuthorship W2335251708A5025465922 @default.
- W2335251708 hasConcept C127413603 @default.
- W2335251708 hasConcept C128765274 @default.
- W2335251708 hasConcept C148280534 @default.
- W2335251708 hasConcept C15133125 @default.
- W2335251708 hasConcept C177418412 @default.
- W2335251708 hasConcept C178790620 @default.
- W2335251708 hasConcept C185592680 @default.